Newly released Phase 2 data shows that NS002 has the potential to outperform in epinephrine delivery, with notable enhancements in early absorption in comparison to EpiPen®. The results were statistically significant, indicating a promising lead over the current standard. A pivotal study is scheduled for the fourth quarter of 2026 to further assess NS002's capabilities in this area.